Skip to main content
. 2023 May 18;9(2):e12382. doi: 10.1002/trc2.12382

FIGURE 1.

FIGURE 1

Exposure (aducanumab concentration)–CDR‐SB response (disease progression slope quantifying how fast the clinical endpoint deteriorated over time) relationship. A, Overall groups. B, Subgroups based on Pre‐PV4 and Post‐PV4. CDR‐SB, Clinical Dementia Rating Sum of Boxes; Low, low dose; High, high dose; PV4, Protocol Version 4.